SSA
CAPR icon

Schonfeld Strategic Advisors’s Capricor Therapeutics CAPR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,815
Closed -$330K – 2075
2025
Q1 		$330K Buy
+34,815
New +$483K ﹤0.01% 1749
2024
Q4 		– Sell
-90,365
Closed -$1.37M – 2038
2024
Q3 		$1.37M Buy
+90,365
New +$447K 0.01% 1040

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
BDF
Black Diamond Financial Towson, Maryland $916M AUM 15.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Schonfeld Strategic Advisors's CAPR Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Capricor Therapeutics (CAPR) in Q2 2025, closing a stake of 34,815 shares — an estimated $330K sold.

Schonfeld Strategic Advisors first reported a position in CAPR in Q3 2024 and held it in 2 quarters. The position peaked at $1.37M in Q3 2024. 107 funds tracked by Wall St. Rank hold CAPR as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Capricor Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 34,815 Capricor Therapeutics shares in Q2 2025, an estimated $330K.
  • Schonfeld Strategic Advisors first reported a position in Capricor Therapeutics in Q3 2024 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Capricor Therapeutics position peaked at $1.37M in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.